FIELD: medicine, pharmacy.
SUBSTANCE: invention refers to biotechnology, namely to stable pharmaceutical compositions of fused protein TNFR: Fc. Pharmaceutical compositions and kits for their application of different physical stability TNFR:Fc are obtained by using the citrate buffer system at a concentration of 25 to 120 mM and amino acid selected from the group consisting of proline and lysine, and their pharmaceutically acceptable salts at a concentration of 15 to 100 mM as a stabilizer.
EFFECT: invention allows stability of pharmaceutical compositions of etanercept for long-term storage.
50 cl, 1 dwg, 17 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| STABLE PHARMACEUTICAL COMPOSITION OF TNFR: FC FUSION PROTEIN | 2013 |
|
RU2664691C2 |
| LIQUID COMPOSITION OF POLYPEPTIDES CONTAINING FC DOMAIN OF IMMUNOGLOBULIN | 2011 |
|
RU2600847C2 |
| QUANTITATIVE ESTIMATION OF MISFOLDED TNFR2:Fc | 2015 |
|
RU2698671C2 |
| ALTERNATIVE COMPOSITIONS FOR TNFR:FC CHIMERICAL POLYPEPTIDES | 2014 |
|
RU2663727C2 |
| FUSION PROTEIN PURIFICATION METHOD | 2015 |
|
RU2698654C2 |
| COMPOSITIONS CONTAINING ANAKINRA | 2016 |
|
RU2728795C2 |
| DRUG FORM FOR hGH AND rhIGF-1 COMBINATION+ | 2010 |
|
RU2558821C2 |
| STABLE LIQUID ETANERCEPT COMPOSITION | 2012 |
|
RU2575619C2 |
| PHARMACEUTICAL COMPOSITION OF THE FUSION PROTEIN OF THE TRANSFORMING GROWTH FACTOR BETA RECEPTOR AND ITS APPLICATION | 2019 |
|
RU2791683C2 |
| STABLE BINDING PREPARATIONS BASED ON IgG4 | 2013 |
|
RU2644214C2 |
